Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.75 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.75 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.75 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.71 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.71 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | FABP3 | P05413 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22532171 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL21795574 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22533153 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Phosphatidyl Serine SCHEMBL20767229 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22498713 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531350 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Phosphatidyl Serine SCHEMBL24802704 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532168 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531357 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532089 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746852-A1 | LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION | Universität Bern (CH) | 2026-05-27 | — | — | EP | claimed |
| CN-122075516-A | Application of PLAC8 as target in preparation of tumor treatment medicines | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026105770-A1 | IMMUNOGENIC COMPOSITION COMPRISING LIPID NANOPARTICLES HAVING IMMUNOGENIC PEPTIDE ENCAPSULATED THEREIN | 国立大学法人徳島大学 | 2026-05-21 | — | — | WO | claimed |
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | NOF CORPORATION (JP) | 2026-04-30 | — | — | US | claimed |
| EP-4346772-B1 | PHOSPHOLIPID FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES INC (US) | 2026-04-01 | — | — | EP | claimed |
| CN-121586573-A | Lipopolymers for intra-articular administration | 伯尔尼大学 | 2026-02-27 | — | — | CN | claimed |
| US-20260054227-A1 | COMPOSITE MEMBRANE AND METHOD OF MAKING THE SAME | H2MO TECH PTE LTD (SG) | 2026-02-26 | — | — | US | claimed |
| US-20260029400-A1 | GAS-FILLED MICROVESICLES WITH LIGAND | BRACCO SUISSE SA (CH) | 2026-01-29 | — | — | US | claimed |
| US-12498621-B2 | Miniaturized adaptive optics with deformable phase plate for digital tilt and aberration correction | APPLE INC. (US) | 2025-12-16 | — | — | US | claimed |
| WO-2022115645-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS, AND RELATED METHODS OF USE | AKAGERA MEDICINES, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| EP-2882421-B1 | LIPOSOME COMPOSITION FOR USE IN PERITONEAL DIALYSIS | ETH ZUERICH (CH) | 2022-06-01 | — | — | EP | claimed |
| US-20220152559-A1 | STABILIZED FILTRATION DEVICE | RETEIN AB (SE) | 2022-05-19 | — | — | US | claimed |
| US-20220142922-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | THE GENERAL HOSPITAL CORPORATION | 2022-05-12 | — | — | US | claimed |
| EP-3982932-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | Dnalite Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | claimed |
| WO-2022076547-A1 | LIPID NANOPARTICLE COMPOSITIONS | PRECISION BIOSCIENCES, INC. (US) | 2022-04-14 | — | — | WO | claimed |
| CN-114329177-A | O2O scene teacher recommendation method based on DPPs | 南京积微信息科技有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-114286671-A | Compositions and methods for biological delivery vehicles | DNALite治疗学公司 | 2022-04-05 | — | — | CN | claimed |
| CN-110563762-B | PPh3Copper complex with dpts, preparation method, application and device thereof | 湖北大学 | 2022-02-08 | — | — | CN | claimed |
| CN-109713098-B | Light emitting diode and light emitting apparatus including the same | 乐金显示有限公司 | 2022-01-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | SREBF1, SREBF2, FABP1 | P2RY10 4842/4885GPR34 3787/4885GPR174 3668/4885 |
| US-20260029400-A1 | GAS-FILLED MICROVESICLES WITH LIGAND | EPCAM, PLTP, PHOSPHO1 | P2RY10 2292/4885GPR34 1230/4885GPR174 144/4885 |
| US-20260054227-A1 | COMPOSITE MEMBRANE AND METHOD OF MAKING THE SAME | AQP1, AQP4, AQP3 | P2RY10 376/4885GPR34 4314/4885GPR174 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.